This review provides a broad overview of traditional immunotherapeutic approaches, more recent monoclonal antibody (mAb)-mediated targeting of immune checkpoints (PD-1/PD-L1, CTLA-4), and molecular targeting of aberrant signaling molecules (BRAF and MEK), using specific inhibitors for the treatment of melanoma. Here, MAP2K7 is linked to melanoma.